Fusion Medical to develop FloSeal sealant from $9 million share offering
This article was originally published in Clinica
Executive Summary
Fusion Medical Technologies plans to raise $9.3 million which will be used largely to commercialise FloSeal, a collagen-derived matrix with thrombin that controls surgical bleeding. In a secondary offering, the company intends to sell 1.7 million shares at an assumed offering price of around $6.17.